Asaf Danziger's most recent trade in NovoCure Ltd was a trade of 833 Ordinary Shares done at an average price of $15.1 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Asaf Danziger | Director | Grant, award, or other acquisition of securities at price $ 15.13 per share. | 30 Jun 2025 | 833 | 416,473 (0%) | 0% | 15.1 | 12,603 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 400,000 | 415,640 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director | Grant, award, or other acquisition of securities at price $ 14.75 per share. | 01 Jan 2025 | 412 | 15,640 (0%) | 0% | 14.7 | 6,076 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 12.24 per share. | 28 Jun 2024 | 1,239 | 15,228 (0%) | 0% | 12.2 | 15,165 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 35.28 per share. | 30 Jun 2023 | 367 | 13,989 (0%) | 0% | 35.3 | 12,948 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 187,500 | 13,583 (0%) | 0% | 108 | 20,250,000 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 187,500 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 05 Jan 2023 | 187,500 | 201,083 (0%) | 0% | 7.2 | 1,340,625 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 25,000 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 05 Jan 2023 | 25,000 | 38,583 (0%) | 0% | 11.5 | 286,500 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 111.23 per share. | 05 Jan 2023 | 8,369 | 30,214 (0%) | 0% | 111.2 | 930,916 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 114.35 per share. | 05 Jan 2023 | 4,568 | 23,646 (0%) | 0% | 114.4 | 522,362 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 115.21 per share. | 05 Jan 2023 | 3,702 | 19,944 (0%) | 0% | 115.2 | 426,512 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 118.47 per share. | 05 Jan 2023 | 2,123 | 15,427 (0%) | 0% | 118.5 | 251,515 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 112.86 per share. | 05 Jan 2023 | 2,000 | 28,214 (0%) | 0% | 112.9 | 225,726 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 116.06 per share. | 05 Jan 2023 | 1,395 | 18,549 (0%) | 0% | 116.1 | 161,906 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 119.35 per share. | 05 Jan 2023 | 1,344 | 14,083 (0%) | 0% | 119.3 | 160,405 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 117.01 per share. | 05 Jan 2023 | 999 | 17,550 (0%) | 0% | 117.0 | 116,894 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 119.99 per share. | 05 Jan 2023 | 500 | 13,583 (0%) | 0% | 120.0 | 59,994 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 62.31 per share. | 05 Jan 2023 | 39 | 13,622 (0%) | 0% | 62.3 | 2,430 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 59.08 per share. | 05 Jul 2022 | 276 | 13,583 (0%) | 0% | 59.1 | 16,305 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 13,470 | 13,470 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 63.81 per share. | 06 Jan 2022 | 31 | 13,307 (0%) | 0% | 63.8 | 1,978 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 102.36 per share. | 26 Nov 2021 | 3,870 | 12,172 (0%) | 0% | 102.4 | 396,133 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 103.37 per share. | 26 Nov 2021 | 1,000 | 13,172 (0%) | 0% | 103.4 | 103,370 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 96.50 per share. | 26 Nov 2021 | 104 | 13,276 (0%) | 0% | 96.5 | 10,036 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 118 | 8,302 (0%) | 0% | 137.1 | 16,180 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 196.34 per share. | 13 Apr 2021 | 97,973 | 8,184 (0%) | 0% | 196.3 | 19,236,323 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 9,259 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.10 per share. | 27 Feb 2021 | 9,259 | 206,944 (0%) | 0% | 149.1 | 1,380,517 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 50.66 per share. | 06 Jan 2021 | 53 | 197,685 (0%) | 0% | 50.7 | 2,685 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 103,955 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 103,955 | 103,955 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.00 per share. | 18 Dec 2020 | 103,955 | 301,587 (0%) | 0% | 22 | 2,287,010 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.00 per share. | 18 Dec 2020 | 103,955 | 301,587 (0%) | 0% | 22 | 2,287,010 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 156.08 per share. | 18 Dec 2020 | 24,973 | 255,407 (0%) | 0% | 156.1 | 3,897,861 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 157.04 per share. | 18 Dec 2020 | 24,656 | 231,033 (0%) | 0% | 157.0 | 3,871,904 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 156.09 per share. | 18 Dec 2020 | 24,286 | 255,689 (0%) | 0% | 156.1 | 3,790,826 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 157.01 per share. | 18 Dec 2020 | 23,601 | 231,806 (0%) | 0% | 157.0 | 3,705,522 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 155.24 per share. | 18 Dec 2020 | 21,612 | 279,975 (0%) | 0% | 155.2 | 3,355,047 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 155.23 per share. | 18 Dec 2020 | 21,207 | 280,380 (0%) | 0% | 155.2 | 3,292,005 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 160.25 per share. | 18 Dec 2020 | 12,092 | 205,258 (0%) | 0% | 160.3 | 1,937,743 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 160.27 per share. | 18 Dec 2020 | 11,686 | 205,253 (0%) | 0% | 160.3 | 1,872,915 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 158.06 per share. | 18 Dec 2020 | 10,077 | 221,729 (0%) | 0% | 158.1 | 1,592,811 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 158.09 per share. | 18 Dec 2020 | 9,183 | 221,850 (0%) | 0% | 158.1 | 1,451,777 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 159.27 per share. | 18 Dec 2020 | 4,790 | 216,939 (0%) | 0% | 159.3 | 762,903 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 159.32 per share. | 18 Dec 2020 | 4,500 | 217,350 (0%) | 0% | 159.3 | 716,954 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 161.11 per share. | 18 Dec 2020 | 4,014 | 201,239 (0%) | 0% | 161.1 | 646,679 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 160.99 per share. | 18 Dec 2020 | 3,500 | 201,758 (0%) | 0% | 161.0 | 563,479 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 162.35 per share. | 18 Dec 2020 | 1,700 | 199,539 (0%) | 0% | 162.4 | 276,000 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 162.17 per share. | 18 Dec 2020 | 1,426 | 200,332 (0%) | 0% | 162.2 | 231,259 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 162.97 per share. | 18 Dec 2020 | 1,300 | 199,032 (0%) | 0% | 163.0 | 211,860 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 164.96 per share. | 18 Dec 2020 | 971 | 198,032 (0%) | 0% | 165.0 | 160,175 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 165.38 per share. | 18 Dec 2020 | 700 | 197,832 (0%) | 0% | 165.4 | 115,768 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 163.35 per share. | 18 Dec 2020 | 536 | 199,003 (0%) | 0% | 163.3 | 87,555 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 164.11 per share. | 18 Dec 2020 | 500 | 198,532 (0%) | 0% | 164.1 | 82,055 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 166.08 per share. | 18 Dec 2020 | 400 | 197,632 (0%) | 0% | 166.1 | 66,432 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 166.17 per share. | 18 Dec 2020 | 200 | 197,632 (0%) | 0% | 166.2 | 33,234 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2020 | 103,000 | 207,910 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 99.00 per share. | 15 Sep 2020 | 103,000 | 197,632 (0%) | 0% | 99 | 10,197,000 | Ordinary Shares |
| NovoCure Ltd | Asaf Danziger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.00 per share. | 15 Sep 2020 | 103,000 | 300,632 (0%) | 0% | 22 | 2,266,000 | Ordinary Shares |